MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature ...
PacBio announced a key study published in the American Journal of Human Genetics by Radboud University Medical Center, showcasing the effectiveness of its HiFi long-read sequencing technology for ...
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare ...
PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...
PacBio is known in the genomics space for its HiFi sequencing technology—which provides long, highly accurate reads. But today, the company is announcing its entry into the high-throughput carrier ...
MENLO PARK, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, has delivered its first Vega systems to Berry Genomics as ...
PacBio aims to dive deeper into the family planning market with an updated carrier screening kit designed to take multiple DNA tests that check parents for specific genes and combine them into a ...
Pacific Biosciences of California, Inc. (NASDAQ:PACB) has gained more than 12% over the past month and roughly 35% since the ...
Zacks Investment Research on MSN
Pacific Biosciences of California (PACB) stock sinks as market gains: Here's why
In the latest close session, Pacific Biosciences of California (PACB) was down 2.89% at $1.68. The stock fell short of the S&P 500, which registered a gain of 0.79% for the day. Meanwhile, the Dow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results